PT1299383E - Derivados de sulfonil-pirrolidina uteis para o tratamento de perturbacoes neurologicas - Google Patents

Derivados de sulfonil-pirrolidina uteis para o tratamento de perturbacoes neurologicas

Info

Publication number: PT1299383E
Authority: PT; Portugal
Prior art keywords: treatment; perturbacoes; neurological; pyrrolidine derivatives; useful
Prior art date: 2000-06-30

Application number

PT01960365T

Other languages

English (en)

Inventor

Jurgen Wichmann

Vincent Mutel

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2001-06-22

Publication date

2005-05-31

2001-06-22 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-05-31 Publication of PT1299383E publication Critical patent/PT1299383E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Surgery (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Toxicology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Vascular Medicine (AREA)

PT01960365T 2000-06-30 2001-06-22 Derivados de sulfonil-pirrolidina uteis para o tratamento de perturbacoes neurologicas PT1299383E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00113894		2000-06-30
PCT/EP2001/007135 WO2002002554A1 (en)	2000-06-30	2001-06-22	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Publications (1)

Publication Number	Publication Date
PT1299383E true PT1299383E (pt)	2005-05-31

Family

ID=8169121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT01960365T PT1299383E (pt)	2000-06-30	2001-06-22	Derivados de sulfonil-pirrolidina uteis para o tratamento de perturbacoes neurologicas

Country Status (35)

Country	Link
US (2)	US6589978B2 (pt)
EP (1)	EP1299383B1 (pt)
JP (1)	JP3994051B2 (pt)
KR (1)	KR100529423B1 (pt)
CN (1)	CN1178936C (pt)
AR (1)	AR029288A1 (pt)
AT (1)	ATE286895T1 (pt)
AU (2)	AU2001281877B2 (pt)
BR (1)	BR0112093A (pt)
CA (1)	CA2413243A1 (pt)
CZ (1)	CZ2003280A3 (pt)
DE (1)	DE60108394T2 (pt)
DK (1)	DK1299383T3 (pt)
EC (1)	ECSP024403A (pt)
ES (1)	ES2234869T3 (pt)
HK (1)	HK1058358A1 (pt)
HR (1)	HRP20021023B1 (pt)
HU (1)	HUP0301167A3 (pt)
IL (2)	IL153425A0 (pt)
JO (1)	JO2384B1 (pt)
MA (1)	MA26923A1 (pt)
MX (1)	MXPA02012270A (pt)
MY (1)	MY126903A (pt)
NO (1)	NO324218B1 (pt)
NZ (1)	NZ523025A (pt)
PE (1)	PE20020103A1 (pt)
PL (1)	PL360396A1 (pt)
PT (1)	PT1299383E (pt)
RU (1)	RU2272026C2 (pt)
SI (1)	SI1299383T1 (pt)
TW (1)	TWI265928B (pt)
UY (1)	UY26812A1 (pt)
WO (1)	WO2002002554A1 (pt)
YU (1)	YU99702A (pt)
ZA (1)	ZA200209966B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7256186B2 (en)	2002-02-06	2007-08-14	Schering Corporation	Gamma secretase inhibitors
US20040171614A1 (en) *	2002-02-06	2004-09-02	Schering-Plough Corporation	Novel gamma secretase inhibitors
TW200302717A (en) *	2002-02-06	2003-08-16	Schering Corp	Novel gamma secretase inhibitors
DE10240818A1 (de) *	2002-08-30	2004-05-13	Grünenthal GmbH	Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
GB0225938D0 (en) *	2002-11-06	2002-12-11	Glaxo Group Ltd	Novel compounds
KR20070010144A (ko) *	2004-04-05	2007-01-22	쉐링 코포레이션	신규한 감마 세크레타제 억제제
US20060035884A1 (en) *	2004-05-20	2006-02-16	Elan Pharmaceuticals, Inc.	N-cyclic sulfonamido inhibitors of gamma secretase
MX2007000040A (es)	2004-06-30	2007-03-07	Schering Corp	N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas.
AR049726A1 (es) *	2004-07-22	2006-08-30	Schering Corp	Amidas sustituidas inhibidoras de beta secretasa
JP5173192B2 (ja)	2004-09-30	2013-03-27	武田薬品工業株式会社	プロトンポンプ阻害薬
AR054435A1 (es) *	2005-04-04	2007-06-27	Takeda Pharmaceutical	Agente para profilaxis o terapia contra la depresion o desorden de ansiedad
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
ES2364498T3 (es)	2005-08-30	2011-09-05	Takeda Pharmaceutical Company Limited	Inhibidor de la secreción ácida.
CA2625153A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AU2007249435A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008040492A1 (de) *	2006-09-29	2008-04-10	Grünenthal GmbH	Substituierte sulfonamid-derivate
US8933105B2 (en)	2007-02-28	2015-01-13	Takeda Pharmaceutical Company Limited	Pyrrole compounds
EP2315591B1 (en) *	2008-08-15	2016-03-16	Nivalis Therapeutics, Inc.	Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
UA105185C2 (uk)	2008-08-27	2014-04-25	Такеда Фармасьютікал Компані Лімітед	Піроли
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2351323B1 (es) *	2009-06-26	2011-10-05	Institut Univ. De Ciència I Tecnologia, S.A.	Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) *	2009-07-01	2011-10-05	Institut Univ. De Ciència I Tecnologia, S.A.	Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
JPWO2022270628A1 (pt) *	2021-06-25	2022-12-29

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3905979A (en) *	1974-05-09	1975-09-16	Stanford Research Inst	Diazabicyclooctanes and diazabicycloheptanes
US4539411A (en) *	1982-02-05	1985-09-03	Hoffmann-La Roche Inc.	Rhodium complexes of chiral phosphines
US5036153A (en) *	1989-05-11	1991-07-30	Braish Tamim F	Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
GB9612884D0 (en)	1996-06-20	1996-08-21	Smithkline Beecham Plc	Novel compounds
US5721256A (en)	1997-02-12	1998-02-24	Gpi Nil Holdings, Inc.	Method of using neurotrophic sulfonamide compounds
WO1999026615A1 (en)	1997-11-24	1999-06-03	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
US6645939B1 (en) *	1997-11-24	2003-11-11	Merck & Co., Inc.	Substituted β-alanine derivatives as cell adhesion inhibitors
GB9804426D0 (en)	1998-03-02	1998-04-29	Pfizer Ltd	Heterocycles
AT411339B (de)	1998-05-13	2003-12-29	Fronius Schweissmasch Prod	Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür
PL345110A1 (en)	1998-06-03	2001-12-03	Gpi Nil Holdings	Aza-heterocyclic compounds used to treat neurological disorders and hair loss
EP1140904B1 (en)	1998-12-18	2005-04-20	Schering Corporation	Farnesyl protein transferase inhibitors
CN1353701A (zh) *	1999-01-27	2002-06-12	奥索-麦克尼尔药品公司	用作类胰蛋白酶抑制剂的肽基杂环酮类化合物
TW575561B (en) *	1999-03-25	2004-02-11	Hoffmann La Roche	1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
CA2374767C (en) *	1999-05-20	2007-05-15	Dong Wha Pharm. Ind. Co., Ltd.	Optically active quinoline carboxylic acid derivatives having 7-pyrrolidine substitutes causing optical activity and a process for preparing thereof
US6143776A (en) *	2000-02-02	2000-11-07	Sunesis Pharmaceuticals, Inc.	Tosylproline analogs as thymidylate synthase inhibitors

2001
- 2001-06-13 US US09/880,539 patent/US6589978B2/en not_active Expired - Fee Related
- 2001-06-14 TW TWSULFONYL-A patent/TWI265928B/zh not_active IP Right Cessation
- 2001-06-22 JP JP2002507806A patent/JP3994051B2/ja not_active Expired - Fee Related
- 2001-06-22 BR BR0112093-0A patent/BR0112093A/pt not_active IP Right Cessation
- 2001-06-22 SI SI200130290T patent/SI1299383T1/xx unknown
- 2001-06-22 KR KR10-2002-7017967A patent/KR100529423B1/ko not_active IP Right Cessation
- 2001-06-22 HU HU0301167A patent/HUP0301167A3/hu unknown
- 2001-06-22 MX MXPA02012270A patent/MXPA02012270A/es active IP Right Grant
- 2001-06-22 EP EP01960365A patent/EP1299383B1/en not_active Expired - Lifetime
- 2001-06-22 AU AU2001281877A patent/AU2001281877B2/en not_active Ceased
- 2001-06-22 PL PL36039601A patent/PL360396A1/xx unknown
- 2001-06-22 ES ES01960365T patent/ES2234869T3/es not_active Expired - Lifetime
- 2001-06-22 CZ CZ2003280A patent/CZ2003280A3/cs unknown
- 2001-06-22 AT AT01960365T patent/ATE286895T1/de not_active IP Right Cessation
- 2001-06-22 YU YU99702A patent/YU99702A/sh unknown
- 2001-06-22 IL IL15342501A patent/IL153425A0/xx active IP Right Grant
- 2001-06-22 WO PCT/EP2001/007135 patent/WO2002002554A1/en active IP Right Grant
- 2001-06-22 RU RU2003100516/04A patent/RU2272026C2/ru not_active IP Right Cessation
- 2001-06-22 PT PT01960365T patent/PT1299383E/pt unknown
- 2001-06-22 NZ NZ523025A patent/NZ523025A/en unknown
- 2001-06-22 AU AU8187701A patent/AU8187701A/xx active Pending
- 2001-06-22 DE DE60108394T patent/DE60108394T2/de not_active Expired - Fee Related
- 2001-06-22 CA CA002413243A patent/CA2413243A1/en not_active Abandoned
- 2001-06-22 CN CNB01812061XA patent/CN1178936C/zh not_active Expired - Fee Related
- 2001-06-22 DK DK01960365T patent/DK1299383T3/da active
- 2001-06-26 JO JO2001100A patent/JO2384B1/en active
- 2001-06-27 MY MYPI20013048 patent/MY126903A/en unknown
- 2001-06-27 PE PE2001000638A patent/PE20020103A1/es not_active Application Discontinuation
- 2001-06-27 AR ARP010103053A patent/AR029288A1/es not_active Application Discontinuation
- 2001-06-29 UY UY26812A patent/UY26812A1/es not_active Application Discontinuation
2002
- 2002-12-09 ZA ZA200209966A patent/ZA200209966B/en unknown
- 2002-12-12 IL IL153425A patent/IL153425A/en not_active IP Right Cessation
- 2002-12-20 HR HR20021023A patent/HRP20021023B1/xx not_active IP Right Cessation
- 2002-12-26 EC EC2002004403A patent/ECSP024403A/es unknown
- 2002-12-27 MA MA26983A patent/MA26923A1/fr unknown
- 2002-12-27 NO NO20026263A patent/NO324218B1/no unknown
2003
- 2003-03-26 US US10/397,908 patent/US6995182B2/en not_active Expired - Fee Related
2004
- 2004-02-16 HK HK04101071A patent/HK1058358A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
TWI265928B (en)	2006-11-11
KR100529423B1 (ko)	2005-11-17
NO20026263D0 (no)	2002-12-27
NO20026263L (no)	2002-12-27
CZ2003280A3 (cs)	2003-12-17
MA26923A1 (fr)	2004-12-20
JO2384B1 (en)	2007-06-17
MY126903A (en)	2006-10-31
ZA200209966B (en)	2004-03-09
US6589978B2 (en)	2003-07-08
AU2001281877B2 (en)	2006-08-31
BR0112093A (pt)	2003-05-13
JP3994051B2 (ja)	2007-10-17
EP1299383A1 (en)	2003-04-09
HUP0301167A2 (hu)	2003-08-28
ATE286895T1 (de)	2005-01-15
DE60108394D1 (de)	2005-02-17
HRP20021023B1 (en)	2006-08-31
RU2272026C2 (ru)	2006-03-20
DK1299383T3 (da)	2005-05-23
CN1178936C (zh)	2004-12-08
WO2002002554A1 (en)	2002-01-10
EP1299383B1 (en)	2005-01-12
NZ523025A (en)	2004-04-30
PL360396A1 (en)	2004-09-06
PE20020103A1 (es)	2002-02-13
HK1058358A1 (en)	2004-05-14
US6995182B2 (en)	2006-02-07
ECSP024403A (es)	2003-02-06
YU99702A (sh)	2006-05-25
AR029288A1 (es)	2003-06-18
IL153425A (en)	2007-08-19
ES2234869T3 (es)	2005-07-01
JP2004502688A (ja)	2004-01-29
MXPA02012270A (es)	2003-04-25
SI1299383T1 (en)	2005-06-30
IL153425A0 (en)	2003-07-06
HRP20021023A2 (en)	2004-08-31
NO324218B1 (no)	2007-09-10
US20030212066A1 (en)	2003-11-13
DE60108394T2 (de)	2006-03-02
US20020019424A1 (en)	2002-02-14
KR20030011378A (ko)	2003-02-07
AU8187701A (en)	2002-01-14
UY26812A1 (es)	2001-12-28
HUP0301167A3 (en)	2009-12-28
CN1440405A (zh)	2003-09-03
CA2413243A1 (en)	2002-01-10

Publication	Publication Date	Title
PT1299383E (pt)	2005-05-31	Derivados de sulfonil-pirrolidina uteis para o tratamento de perturbacoes neurologicas
BR0115411A (pt)	2004-08-17	Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
JO2285B1 (en)	2005-09-12	Dihydro-benzoic derivatives
UA87653C2 (en)	2009-08-10	1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate
WO2003053359A3 (en)	2004-04-15	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
ME00545B (me)	2011-10-10	Terapeutske kombinacije koje sadrže amlodipin i atorvastatin
PT1259489E (pt)	2006-08-31	Compostos azapoliciclicos condensados con arilo.
TNSN98203A1 (fr)	2005-03-15	Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
ATE360633T1 (de)	2007-05-15	N-substituierte hydromorphone und ihre anwendung
IL162214A (en)	2011-08-31	Pyridine derivatives and pharmaceutical compositions containing the same
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
DE60133389D1 (de)	2008-05-08	Gabapentinanaloga für schlafstörungen
TNSN97044A1 (fr)	2005-03-15	Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
BR0316723A (pt)	2005-10-18	Derivados de anilinopirazol úteis para o tratamento de diabetes
AU4179399A (en)	1999-11-16	Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
NO975028L (no)	1997-12-30	Piperazinoderivater som neurokininantagonister
DE69917005D1 (de)	2004-06-09	Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR9812531A (pt)	2000-07-25	Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
HUP0300863A2 (hu)	2003-09-29	N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
MX9405209A (es)	1995-01-31	Uso de las n-(piridinil)-1h-indol-1-aminas en la preparacion de unmedicamento para el tratamiento de desordenes obsesivo-compulsivos.
BR0007183A (pt)	2002-02-05	Isonipectoamidas para o tratamento de distúrbios mediados por integrina
BR0104005A (pt)	2002-07-09	Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
ATE242766T1 (de)	2003-06-15	Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
EA200200750A1 (ru)	2003-02-27	Новое терапевтическое применение еноксапарина
BR0203861A (pt)	2003-09-16	Processo para preparação de alcanossulfonilpiridinas